News AbbVie to file long-acting psoriasis contender AbbVie hopes risankizumab will rebuild sales after Humira patent expires
News Bioelectronic wearable shows promise in psoriasis Thync's bioelectronic wearable significantly reduced symptoms in psoriasis patients within four weeks of use.
News J&J's psoriasis drug faces crowded market after US approval J&J taking on next gen drugs from Novartis, Eli Lilly, and Valeant.
News Novartis' psoriasis drug gets label boost New label shows Cosentyx is superior to J&J's rival in long-term.
News Valeant's Siliq price undercuts rivals to offset black box w... Siliq will be cheaper than rivals from Novartis and Eli Lilly.
News Novartis cues up Cosentyx as disease-modifying treatment for... Pharma begins early intervention trial after Cosentyx shows "disease modifying" properties
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
